Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Doxorubicin pathways: pharmacodynamics and adverse effects.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56. No abstract available.

PMID:
21048526
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

How could we solve the diagnostic dilemma of doxorubicin toxicity in high-risk patients?

Davutoglu V, Soydinc S, Akdemir I.

J Natl Med Assoc. 2004 May;96(5):689-90. No abstract available.

PMID:
15160987
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ.

J Pharm Pharm Sci. 2007;10(3):350-7.

PMID:
17727798
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).

Working PK, Dayan AD.

Hum Exp Toxicol. 1996 Sep;15(9):751-85. Review. No abstract available.

PMID:
8880211
[PubMed - indexed for MEDLINE]
5.

Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.

David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG.

Int J Oncol. 2000 Dec;17(6):1077-86.

PMID:
11078791
[PubMed - indexed for MEDLINE]
6.

cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways.

Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE.

J Pharmacol Exp Ther. 2001 Nov;299(2):434-41.

PMID:
11602652
[PubMed - indexed for MEDLINE]
Free Article
7.

Time-schedule dependency of S 16020, a new topoisomerase II inhibitor.

Soudon J, Milano G, Poullain MG, Fischel JL, Formento P, Berlion M, Giroux B.

Anticancer Drugs. 1999 Jul;10(6):597-604.

PMID:
10885908
[PubMed - indexed for MEDLINE]
8.

Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.

Lal S, Mahajan A, Chen WN, Chowbay B.

Curr Drug Metab. 2010 Jan;11(1):115-28. Review.

PMID:
20302569
[PubMed - indexed for MEDLINE]
9.

[Inhibition of hydrogen peroxide, oxygen and semiquinone radicals in the development of drug resistance to doxorubicin in human erythroleukemia K562-cells].

Kalishina EV, Saprin AN, Solomka VS, Shchebrak NP, Piruzian LA.

Vopr Onkol. 2003;49(3):294-8. Review. Russian. No abstract available.

PMID:
12926210
[PubMed - indexed for MEDLINE]
10.

Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D.

Int J Cancer. 2001 Aug 15;93(4):571-6.

PMID:
11477562
[PubMed - indexed for MEDLINE]
11.

Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.

Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K.

Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4.

PMID:
11031728
[PubMed - indexed for MEDLINE]
12.

Development and activities of the BR96-doxorubicin immunoconjugate.

Hellström I, Hellström KE, Senter PD.

Methods Mol Biol. 2001;166:3-16. Review. No abstract available.

PMID:
11217374
[PubMed - indexed for MEDLINE]
13.

Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae.

Xia L, Jaafar L, Cashikar A, Flores-Rozas H.

Cancer Res. 2007 Dec 1;67(23):11411-8.

PMID:
18056469
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation.

Fimognari C, Lenzi M, Sciuscio D, Cantelli-Forti G, Hrelia P.

Ann N Y Acad Sci. 2007 Jan;1095:62-9.

PMID:
17404018
[PubMed - indexed for MEDLINE]
15.

Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53.

Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC, Borner MM.

J Natl Cancer Inst. 2000 Sep 20;92(18):1535-6. No abstract available.

PMID:
10995814
[PubMed - indexed for MEDLINE]
Free Article
16.

Radiation- and chemoinduced multidrug resistance in colon carcinoma cells.

Bartkowiak D, Stempfhuber M, Wiegel T, Bottke D.

Strahlenther Onkol. 2009 Dec;185(12):815-20. doi: 10.1007/s00066-009-1993-9. Epub .

PMID:
20013091
[PubMed - indexed for MEDLINE]
17.

A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.

Ludke AR, Al-Shudiefat AA, Dhingra S, Jassal DS, Singal PK.

Can J Physiol Pharmacol. 2009 Oct;87(10):756-63. doi: 10.1139/Y09-059. Review.

PMID:
19898559
[PubMed - indexed for MEDLINE]
18.

The anticancer drug-DNA complex: femtosecond primary dynamics for anthracycline antibiotics function.

Qu X, Wan C, Becker HC, Zhong D, Zewail AH.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14212-7. Epub 2001 Nov 27.

PMID:
11724924
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.

Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K.

Br J Cancer. 2001 Apr 6;84(7):959-64.

PMID:
11286477
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.

Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S.

Eur J Pharm Sci. 2012 Aug 15;46(5):484-91. doi: 10.1016/j.ejps.2012.03.012. Epub 2012 Mar 30.

PMID:
22484209
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk